Bionik Laboratories Corp.
BNKL
$0.00
$0.000.00%
OTC PK
| 03/31/2023 | 12/31/2022 | 09/30/2022 | 06/30/2022 | 03/31/2022 | |
|---|---|---|---|---|---|
| Net Income | -26.03% | 4.71% | 18.40% | 18.83% | 75.58% |
| Total Depreciation and Amortization | -1.51% | 60.48% | 9.73% | -12.40% | -57.98% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 373.91% | -14.90% | 30.16% | -84.13% | -93.79% |
| Change in Net Operating Assets | -40.36% | 440.25% | -42.34% | 500.78% | 57.68% |
| Cash from Operations | -47.60% | 46.32% | 17.81% | 15.77% | 0.84% |
| Capital Expenditure | 0.00% | 88.89% | -- | -- | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | 100.00% | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 0.00% | 99.64% | -- | -- | 100.00% |
| Total Debt Issued | -37.50% | 220.00% | -50.00% | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | 200.00% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -37.50% | 220.00% | -50.00% | 35,614.29% | 200.00% |
| Foreign Exchange rate Adjustments | -110.00% | 127.78% | -1,100.00% | -50.00% | -122.22% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -189.67% | 130.88% | -40.51% | 51.94% | 1.86% |